摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-methoxy-1H-imidazole | 88945-43-1

中文名称
——
中文别名
——
英文名称
4-methoxy-1H-imidazole
英文别名
5-Methoxy-1h-imidazole
4-methoxy-1H-imidazole化学式
CAS
88945-43-1
化学式
C4H6N2O
mdl
MFCD21336080
分子量
98.1044
InChiKey
YXSUIVZFLAJASX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    288.2±13.0 °C(Predicted)
  • 密度:
    1.154±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    7
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    37.9
  • 氢给体数:
    1
  • 氢受体数:
    2

SDS

SDS:b75d3594dc30b716ce533885ef79190e
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS OXADIAZINE ET LEURS MÉTHODES D'UTILISATION
    申请人:FORUM PHARMCEUTICALS INC
    公开号:WO2016201168A1
    公开(公告)日:2016-12-15
    The present disclosure relates to oxadiazine compounds, pharmaceutical compositions comprising an effective amount of an oxadiazine compound and methods for using an oxadiazine compound in the treatment of a neurodegenerative disease, comprising administering to a subject in need thereof an effective amount of an oxadiazine compound.
    本公开涉及恶二嗪化合物,包含有效量的恶二嗪化合物的药物组合物,以及使用恶二嗪化合物治疗神经退行性疾病的方法,包括向需要其的受试者施用有效量的恶二嗪化合物。
  • Palladium(0)-catalyzed allylation of 4(5)-substituted imidazoles, 5(6)-substituted benzimidazoles, benzotriazole and 5(6)-methylbenzotriazole
    作者:N. Arnau、Y. Arredondo、M. Moreno-Mañas、R. Pleixats、M. Villarroya
    DOI:10.1002/jhet.5570320438
    日期:1995.7
    Pd(0)-Catalyzed allylations of 4(5)-nitroimidazole, 1, 2-methyl-4(5)-nitroimidazole, 2, 4(5)-bromo-imidazole, 7, 4(5)-methoxyimidazole, 10, 5(6)-nitrobenzimidazole, 16a, 5(6)-methylbenzimidazole, 16b, benzotriazole, 19, and 5(6)-methylbenzotriazole, 22, were studied under several reaction conditions. Nitroimidazoles 1 and 2 were regioselectively allylated under thermodynamic control, leading to 1-allyl-4-nitro
    的Pd(0)的4(5) -硝基咪唑催化的烯丙基化,1,2-甲基-4(5) -硝基咪唑,2,4(5) -溴咪唑,7,4(5)-methoxyimidazole,10,在几种反应条件下研究了5(6)-硝基苯并咪唑16a,5(6)-甲基苯并咪唑16b,苯并三唑19和22(5)-甲基苯并三唑22。在热力学控制下将硝基咪唑1和2区域选择性烯丙基化,生成1-allyl-4-nitro衍生物。
  • [EN] PYRIMIDINE COMPOUNDS AND THEIR USE AS GAMMA SECRETASE MODULATORS<br/>[FR] COMPOSÉS DE PYRIMIDINE ET LEUR UTILISATION COMME MODULATEURS DE LA GAMMA-SÉCRÉTASE
    申请人:ACTURUM LIFE SCIENCE AB
    公开号:WO2014195323A1
    公开(公告)日:2014-12-11
    The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases.
    本发明涉及式(I)化合物及其药用可接受的盐。该发明还涉及包含这些化合物的药物组合物,制造这些化合物的方法,以及它们作为治疗和/或预防Aβ相关疾病的药物的应用。
  • [EN] IMIDAZOBENZAZEPINE COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM (CNS) DISEASES<br/>[FR] COMPOSÉS IMIDAZOBENZAZÉPINE POUR LE TRAITEMENT DES MALADIES DU SYSTÈME NERVEUX CENTRAL (SNC)
    申请人:GLAXO GROUP LTD
    公开号:WO2010142652A1
    公开(公告)日:2010-12-16
    This invention relates to novel novel imidazobenzazepine derivatives of formula (I) or a pharmaceutically acceptable salt thereof, for treating diseases and conditions of the central nervous system (CNS), in particular sleep disorders.
    这项发明涉及一种新颖的咪唑苯并蒽啉类衍生物的公式(I)或其药用可接受的盐,用于治疗中枢神经系统(CNS)的疾病和病况,特别是睡眠障碍。
  • Pyrimidine compounds and their use as gamma secretase modulators
    申请人:Acturum Life Science AB
    公开号:US09439904B2
    公开(公告)日:2016-09-13
    The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The invention also relates to pharmaceutical compositions comprising these compounds, to processes for making these compounds, and to their use as medicaments for treatment and/or prevention of Aβ-related diseases.
    本发明涉及式(I)化合物及其药学上可接受的盐。本发明还涉及包含这些化合物的制药组合物,制备这些化合物的方法,以及它们作为治疗和/或预防Aβ相关疾病的药物的用途。
查看更多